Published in Clin Cancer Res on September 14, 2011
Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer (2013) 2.44
Progress and Trends in Complement Therapeutics. Adv Exp Med Biol (2013) 1.20
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia (2015) 1.01
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. MAbs (2014) 0.91
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ (2013) 0.83
Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition. Oncogene (2015) 0.82
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology (2015) 0.81
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. Mol Ther (2012) 0.80
Protein engineering to target complement evasion in cancer. FEBS Lett (2013) 0.80
Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol (2014) 0.80
Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro. PLoS One (2014) 0.79
Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity. Curr Pharm Des (2012) 0.78
Rapid degradation of the complement regulator, CD59, by a novel inhibitor. J Biol Chem (2014) 0.77
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 3.59
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 3.38
Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol (2007) 2.99
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol (2003) 2.24
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol (2004) 1.96
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood (2002) 1.66
Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene (2007) 1.49
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol (2008) 1.46
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
Complement-regulatory proteins in ovarian malignancies. Int J Cancer (1997) 1.44
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res (2010) 1.37
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist (2008) 1.30
Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol (2000) 1.28
Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res (2009) 1.23
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood (2002) 1.17
Rituximab in chronic lymphocytic leukemia. Semin Hematol (2010) 1.17
Update in the management of chronic lymphocytic leukemia. J Hematol Oncol (2009) 1.14
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol (2010) 1.11
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol (2009) 1.09
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res (2008) 1.07
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol (2005) 1.04
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs (2009) 1.02
Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res (2011) 1.02
In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res (2009) 0.99
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res (2005) 0.99
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer (1997) 0.94
Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr Opin Mol Ther (2008) 0.94
Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci (2009) 0.90
Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. Cell Mol Immunol (2011) 0.90
Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol (1997) 0.87
Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J Cell Physiol (2000) 0.87
Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scand J Immunol (2006) 0.84
An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res (2009) 0.84
Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. Clin Ter (2000) 0.83
Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2010) 0.82
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother (2005) 0.80
Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood (2008) 0.78
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature (2004) 3.65
Plant immunity requires conformational changes [corrected] of NPR1 via S-nitrosylation and thioredoxins. Science (2008) 3.43
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 2.66
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells. Proc Natl Acad Sci U S A (2008) 2.33
Repair of Stanford type A aortic dissection with ascending aorta and hemiarch replacement combined with stent-graft elephant trunk technique by using innominate cannulation. J Thorac Cardiovasc Surg (2011) 2.21
DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem (2002) 2.16
UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett (2008) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
The anterior cruciate ligament remnant: to leave it or not? Arthroscopy (2013) 2.13
Confocal microwave imaging for breast cancer detection: localization of tumors in three dimensions. IEEE Trans Biomed Eng (2002) 2.01
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Quantum plasmon resonances controlled by molecular tunnel junctions. Science (2014) 1.89
Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem (2003) 1.88
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Emerging strategies of lignin engineering and degradation for cellulosic biofuel production. Curr Opin Biotechnol (2008) 1.85
Elastic backscattering spectroscopic microscopy. Opt Lett (2005) 1.84
Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol (2004) 1.77
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant (2008) 1.69
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther (2010) 1.68
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat (2011) 1.68
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene (2012) 1.64
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol (2012) 1.57
Prevention of chylothorax complicating extensive esophageal resection by mass ligation of thoracic duct: a random control study. Ann Thorac Surg (2011) 1.55
A Phantom Study of Magnetoacoustic Tomography with Magnetic Induction (MAT-MI) for Imaging Electrical Impedance of Biological Tissue. J Appl Phys (2006) 1.48
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.46
Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol (2012) 1.45
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.43
Retracted A meta-analysis of external fixator versus intramedullary nails for open tibial fracture fixation. J Orthop Surg Res (2014) 1.42
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun (2007) 1.41
Magnetoacoustic tomographic imaging of electrical impedance with magnetic induction. Appl Phys Lett (2007) 1.41
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer (2010) 1.40
Convergent evolution of syringyl lignin biosynthesis via distinct pathways in the lycophyte Selaginella and flowering plants. Plant Cell (2010) 1.38
The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood (2010) 1.35
Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents (2011) 1.35
Estimation of oxygen saturation from erythrocytes by high-resolution spectroscopic optical coherence tomography. Opt Lett (2010) 1.35
Loss-of-function mutations in the PRPS1 gene cause a type of nonsyndromic X-linked sensorineural deafness, DFN2. Am J Hum Genet (2010) 1.34
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem (2003) 1.34
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Independent origins of syringyl lignin in vascular plants. Proc Natl Acad Sci U S A (2008) 1.31
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist (2008) 1.30
TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer (2011) 1.30
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
Cortical reorganization consistent with spike timing-but not correlation-dependent plasticity. Nat Neurosci (2007) 1.29
Refolding hydrogels self-assembled from N-(2-hydroxypropyl)methacrylamide graft copolymers by antiparallel coiled-coil formation. Biomacromolecules (2006) 1.28
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood (2008) 1.27
Self-assembled supramolecular hydrogels formed by biodegradable PEO-PHB-PEO triblock copolymers and alpha-cyclodextrin for controlled drug delivery. Biomaterials (2006) 1.26
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res (2009) 1.23
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther (2012) 1.23
PTPN14 is required for the density-dependent control of YAP1. Genes Dev (2012) 1.23
Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem (2004) 1.22
Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet (2011) 1.22
Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet (2001) 1.21
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
3D current source density imaging based on the acoustoelectric effect: a simulation study using unipolar pulses. Phys Med Biol (2011) 1.20
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer (2014) 1.18
The structure of the harmonin/sans complex reveals an unexpected interaction mode of the two Usher syndrome proteins. Proc Natl Acad Sci U S A (2010) 1.18
Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci (2014) 1.18
Assembling stable hair cell tip link complex via multidentate interactions between harmonin and cadherin 23. Proc Natl Acad Sci U S A (2009) 1.16
Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res (2010) 1.15
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (2012) 1.15
Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics (2013) 1.14
Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol (2014) 1.13
Impacts of Shewanella oneidensis c-type cytochromes on aerobic and anaerobic respiration. Microb Biotechnol (2010) 1.13
microRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition. Tumour Biol (2013) 1.12
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One (2011) 1.12
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol (2013) 1.12
Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol (2010) 1.12
Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One (2013) 1.11
Analysis of point mutation in site 1896 of HBV precore and its detection in the tissues and serum of HCC patients. World J Gastroenterol (2000) 1.11
Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Dev Immunol (2011) 1.11
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol (2012) 1.11